Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
2011; Oxford University Press; Volume: 103; Issue: 11 Linguagem: Inglês
10.1093/jnci/djr107
ISSN1460-2105
AutoresShuiying Hu, Hongmei Niu, Hiroto Inaba, Shelley Orwick, Charles L. Rose, John C. Panetta, Sheng‐Ping Yang, Stanley Pounds, Yiping Fan, Christopher Calabrese, Jerold E. Rehg, Dario Campana, Jeffrey E. Rubnitz, Sharyn D. Baker,
Tópico(s)Histone Deacetylase Inhibitors Research
ResumoBackgroundAcute myeloid leukemia (AML) is a genetically heterogeneous cancer that frequently exhibits aberrant kinase signaling. We investigated a treatment strategy combining sorafenib, a multikinase inhibitor with limited single-agent activity in AML, and cytarabine, a key component of AML chemotherapy.
Referência(s)